Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 4/20 | 0.37 |
| ▸ | RBP4 | P02753 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28946375 | 0.76 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| Trifluoroacetic Acid SCHEMBL3326076 | 0.76 | SCN9A (0.42) | LPAR1LPAR5 | |
| SCHEMBL3325256 | 0.71 | SLC6A2 (0.47) | — | |
| SCHEMBL3325259 | 0.71 | SLC6A2 (0.47) | — | |
| SCHEMBL3320820 | 0.70 | RBP4 (0.40) | HCRTR1HCRTR2KDM2BLPAR1LPAR5 | |
| SCHEMBL28129909 | 0.67 | SCN9A (0.43) | HCRTR1HCRTR2TTRRBP4 | |
| SCHEMBL8330673 | 0.67 | CHRNB4 (0.34) | — | |
| SCHEMBL27751590 | 0.67 | RBP4 (0.43) | KDM2BTTRRBP4LMNASMN1; SMN2 | |
| SCHEMBL28095478 | 0.66 | ALDH1A1 (0.48) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL27833492 | 0.66 | ALDH1A1 (0.48) | HCRTR1HCRTR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | HCRTR1 918/4885HCRTR2 2201/4885KDM2B 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.